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Th17 cells are a newly identified T cell subset 
that have a specific differentiation program dif-
ferent from traditional Th1 and Th2 cell sub-
sets. The cytokines TGF-, IL-6, IL-1, IL-23, 
and IL-21 are important for the differentiation 
and maintenance of the Th17 lineage (Bettelli 
et al., 2007; Ivanov et al., 2007; McGeachy and 
Cua, 2008; Ouyang et al., 2008; O’Shea et al., 
2009). Th17 cells express and secret the signa-
ture cytokine IL-17. IL-17, also called IL-17A, 
is the most studied member of the IL-17 fam-
ily, consisting of six cytokines (IL-17A to IL-17F; 
Moseley et al., 2003; Kolls and Lindén, 2004; 
Gaffen, 2009). It has been clearly shown that 
IL-17  is  a  major  inflammation-driving  cyto-
kine, exerting its functions through inducing 
and sustaining the production of inflammatory 
cytokines, chemokines, and matrix metallo-
proteinases (MMPs; Ye et al., 2001). IL-17 can 
also act synergistically with IL-1 or TNF for 
further  induction  of  proinflammatory  genes 
(Ruddy et al., 2004; Shen et al., 2005).
Both IL-17 and Th17 cells have been found 
to contribute to the pathogenesis of many in-
flammatory autoimmune disorders in mouse 
models,  including  experimental  autoimmune 
encephalomyelitis  (EAE),  collagen-induced   
arthritis (CIA), and inflammatory bowel disease 
(Nakae et al., 2003; Komiyama et al., 2006; Sato 
et al., 2006; Ogura et al., 2008; Chiang et al., 
2009; Gaffen, 2009; Korn et al., 2009; Reboldi 
et al., 2009). EAE is a well characterized mouse 
model for human multiple sclerosis (MS). It is 
induced by immunization with myelin antigens 
such as myelin oligodendrocyte glycoprotein 
(MOG;  MOG  [35–55])  in  adjuvant  or  by 
adoptive transfer of myelin-specific T cells, re-
sulting in inflammatory infiltrates and demye-
lination in the central nervous system (CNS) 
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Interleukin 17 (IL-17) plays critical roles in the pathogenesis of various autoimmune  
diseases, including experimental autoimmune encephalomyelitis (EAE). How the signals 
triggered by this powerful inflammatory cytokine are controlled to avoid abnormal inflam-
matory responses is not well understood. In this study, we report that TRAF3 is a receptor 
proximal negative regulator of IL-17 receptor (IL-17R) signaling. TRAF3 greatly suppressed 
IL-17–induced NF-B and mitogen-activated protein kinase activation and subsequent 
production of inflammatory cytokines and chemokines. Mechanistically, the binding of 
TRAF3 to IL-17R interfered with the formation of the receptor signaling activation com-
plex IL-17R–Act1–TRAF6, resulting in suppression of downstream signaling. TRAF3 mark-
edly inhibited IL-17–induced expression of inflammatory cytokine and chemokine genes  
in vivo and consequently delayed the onset and greatly reduced the incidence and severity  
of EAE. Thus, TRAF3 is a negative regulator of IL-17R proximal signaling.
© 2010 Zhu et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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RIG-I–mediated type I IFN production for antiviral defense 
(Häcker et al., 2006; Oganesyan et al., 2006; Tseng et al., 
2010). Thus, TRAF3 exerts diverse functions via different 
signaling pathways.
Because IL-17 is a powerful proinflammatory cytokine 
involved in the pathogenesis of a variety of inflammatory   
autoimmune diseases, uncontrolled signaling of IL-17 can 
potentially lead to inflammatory pathology. Although recent 
investigations have begun to dissect the positive signaling 
(Schwandner et al., 2000; Chang et al., 2006; Toy et al., 
2006; Huang et al., 2007; Qian et al., 2007; Liu et al., 2009), 
the  negative  regulation  of  IL-17R–mediated  signaling  re-
mains unclear. In this study, we demonstrate that TRAF3 is 
a crucial negative regulator of IL-17R–mediated signaling. 
TRAF3 interacts with IL-17R in a signal-dependant way. 
Binding of TRAF3 to IL-17R interferes with the formation 
of the positive signaling complex IL-17R–Act1–TRAF6, re-
sulting  in  down-regulation  of  IL-17R–mediated  signaling 
and suppression of IL-17–induced expression of downstream 
inflammatory genes. TRAF3 also controls IL-17–mediated 
induction of inflammatory genes in vivo and consequently 
the development of the autoimmune disease EAE. Our re-
sults identify TRAF3 as the first receptor proximal negative 
regulator in IL-17 signaling and present TRAF3 as a potential 
novel target for intervention of IL-17–dependant auto-
immune diseases.
RESULTS
TRAF3 negatively regulates IL-17–mediated signaling
TRAF3  and  TRAF6  are  important  signaling  adaptors  in 
many signaling pathways such as TNF superfamily receptors 
and  IL-1/TLRs  (Chung  et  al.,  2002;  Jabara  et  al.,  2002; 
Pineda et al., 2007). Previous experiments have shown that 
TRAF6 is required for IL-17–mediated NF-B and JNK   
activation (Schwandner et al., 2000). We tested whether 
TRAF3 has any function in IL-17–mediated pathways. First, 
we transfected TRAF3 or empty vector plasmids into HeLa 
cells  and  checked  IL-17–mediated  immediate  signaling.   
Interestingly,  we  found  that  overexpression  of  TRAF3   
suppressed IL-17–induced IB phosphorylation and degra-
dation, p65 phosphorylation, p38 phosphorylation, and ERK 
phosphorylation, indicating that TRAF3 has general inhibi-
tory effects on IL-17–mediated pathways (Fig. 1 A). We then 
confirmed that through the small interfering RNA (siRNA) 
knockdown approach. HeLa cells were infected with control 
siRNA or TRAF3-specific siRNA lentivirus. siTRAF3 effi-
ciently knocked down TRAF3 expression. Compared with 
control siRNA, TRAF3 knockdown significantly enhanced 
IL-17–mediated  signaling,  which  is  consistent  with  the   
results from TRAF3 overexpression (Fig. 1 B). To further 
confirm this, we moved to check the function of mouse 
TRAF3. To avoid the variation of different mouse embry-
onic fibroblasts (MEFs), we put TRAF3 back into TRAF3-
deficient MEFs through a mouse stem cell virus retroviral 
system. Restoration of TRAF3 greatly inhibited IL-17– 
mediated signaling (Fig. 1 C). Collectively, these data strongly 
and consequently axonal pathology resembling MS (Stromnes 
and Goverman, 2006). IL-17– or IL-17 receptor (IL-17R)–
deficient mice are shown to be resistant to MOG-induced 
EAE (Komiyama et al., 2006; Gonzalez-García et al., 2009). 
Although IL-17 is found to be elevated in human patients 
with autoimmune diseases like MS (Lock et al., 2002), IL-17 
blocking antibody can efficiently reduce autoimmune pathol-
ogy in the mouse model of EAE (Park et al., 2005). These 
studies suggest that IL-17 plays critical roles in the pathogen-
esis of MS or EAE, and targeting IL-17 signaling can poten-
tially be a powerful strategy to cure autoimmune diseases.
IL-17 has been shown to activate many common down-
stream signaling pathways, such as NF-B and mitogen- 
activated protein kinases (MAPKs; c-Jun N-terminal kinase 
[JNK], P38, and extracellular signal-regulated kinase [ERK]; 
Laan et al., 2001; Kolls and Lindén, 2004; Gaffen, 2008; 
Ouyang et al., 2008). TRAF6 was shown to be required for 
IL-17–induced NF-B and JNK activation. However, its in vivo 
function in IL-17–mediated signaling has still not been iden-
tified because of the embryonic lethal phenotype of TRAF6-
deficient mice (Schwandner et al., 2000). Although IL-17R 
does not consist of an obvious TRAF6-binding site, struc-
tural analysis shows it contains a conserved sequence segment 
called SEFIR (SEF and IL-17R), which is similar to the TIR 
(Toll–IL-1 receptor) domain conserved in Toll/IL-1R recep-
tors (Novatchkova et al., 2003). Interestingly, the adaptor Act1 
was found to have the SEFIR domain. We and others discov-
ered that Act1 is required for IL-17–mediated signaling and 
induction of downstream genes (Chang et al., 2006; Qian et al., 
2007). We also found that Act1-deficient mice showed resis-
tance to MOG-induced EAE and dextran sodium sulfate–
induced colitis, supporting the essential role of Act1 in IL-17 
signaling in vivo (Hunter, 2007; Lindén, 2007; Qian et al., 
2007). Interestingly, although IL-17 activates the ERK pathway 
for downstream gene induction (Laan et al., 2001; Sebkova 
et al., 2004), IL-17–mediated ERK activation can also phos-
phorylate and inactivate the transcription factor C/EBP-  
for feedback control (Shen et al., 2009). However, how   
IL-17–mediated  signaling  is  negatively  regulated  is  still 
largely unknown.
TRAF3 is an important negative regulator in TNF family 
receptors like CD40, B cell–activating factor (BAFF) receptor, 
and lymphotoxin  receptor (Cheng et al., 1995; VanArsdale 
et al., 1997; He et al., 2006; Xie et al., 2007; Gardam et al., 
2008). Mechanistically, TRAF3 associates with NIK (NF-B–
inducing kinase) kinase and mediates its degradation through 
the TRAF2–TRAF3–cIAP1–cIAP2 complex in control of 
p100 processing to p52 to suppress B cell survival and im-
mune  responses  in  BAFF-  and  CD40-mediated  pathways 
(Matsuzawa et al., 2008; Vallabhapurapu et al., 2008; Zarnegar 
et al., 2008). However, TRAF3 is essential for oncogene 
LMP1-mediated signaling, which mimics constitutive CD40 
signaling (Xie et al., 2004). TRAF3-deficient mice are peri-
natal lethal, which can be rescued by p100 deficiency (He   
et al., 2006). Interestingly, TRAF3 was also found to be 
commonly  required  for  Toll-like  receptors  (TLRs)  and JEM VOL. 207, November 22, 2010 
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arthritis, we checked the function of TRAF3 in IL-17 signal-
ing  in  human  primary  fibroblast-like  synoviocytes  (FLSs),   
an important cell type for the pathology of rheumatoid ar-
thritis. Similarly, we found that knockdown of TRAF3 in-
creased IL-17–mediated signaling in FLSs (Fig. 1 F). Collectively, 
our data show that endogenous TRAF3 plays a general   
inhibitory role in IL-17 signaling in both cell lines and 
primary cells.
TRAF3 inhibits IL-17–induced expression  
of inflammatory genes
The aforementioned results demonstrated that TRAF3 re-
pressed IL-17–mediated immediate signaling. To explore the 
role of TRAF3 in IL-17–dependant gene transcription, we 
checked  transcription  factor  NF-B  activity  by  luciferase   
assay as an example. HeLa cells were first infected with lenti-
virus encoding GFP and TRAF3 siRNA to knockdown 
suggest that TRAF3 plays a general inhibitory role in IL-17–
mediated pathways.
IL-17 has been shown to play a critical role in the patho-
genesis of autoimmune diseases in mouse models. We wanted 
to know whether endogenous TRAF3 regulates IL-17R sig-
naling in physiologically relevant cell types. Astrocytes are 
reported to be the critical cell type for IL-17 signaling in me-
diating EAE development (Kang et al., 2010). We isolated 
mouse primary astrocytes and performed RNA interference 
(RNAi)–mediated knockdown of mouse TRAF3 through 
lentiviral  system.  We  found  that  knockdown  of  TRAF3 
greatly enhanced IL-17 signaling, whereas knockdown of Act1 
suppressed the signaling in the primary astrocytes (Fig. 1 D). 
We also performed RNAi-mediated knockdown of TRAF3 
in the human astrocyte cell line U87-MG and got the same re-
sults (Fig. 1 E). As IL-17 has also been known to contribute to the 
pathogenesis of CIA, a mouse model for human rheumatoid   
Figure 1.  TRAF3 negatively regulates IL-17–mediated signaling. (A and B) HeLa cells transfected with plasmids for empty vector (EV) or M2 (Flag)-
tagged TRAF3 (A) or infected with lentivirus encoding scrambled siRNA (siNC) or TRAF3 siRNA (siTRAF3; B) were left untreated or treated with IL-17 for 
7.5, 15, or 30 min. Whole cell lysates were immunoblotted with anti–p-IB, anti-IB, anti–p-p65, anti–p-p38, anti-p38, anti–p-ERK, anti-ERK, anti-M2, 
anti-TRAF3, or anti–-actin. (C) Traf3/ MEFs transduced with control retrovirus or retrovirus encoding mouse TRAF3 (M2-TRAF3) were left untreated or 
treated with IL-17 for 7.5, 15, or 30 min. Whole cell lysates were immunoblotted with the indicated antibodies. (D–F) Mouse primary astrocytes (D), U87-
MG astrocyte cell line (E), or human primary synoviocytes (FLS; F) infected with lentivirus encoding scrambled siRNA, TRAF3 siRNA, or Act1 siRNA (siAct1) 
were left untreated or treated with IL-17 for 7.5, 15, or 30 min. Whole cell lysates were immunoblotted with the indicated antibodies. Data are represen-
tative of three (A–C) or two (D–F) independent experiments.2650 TRAF3 suppresses IL-17R signaling | Zhu et al.
Figure 2.  TRAF3 inhibits IL-17–induced expression of inflammatory cytokines and chemokines. (A and B) HeLa cells were transfected with 
plasmids encoding empty vector or TRAF3 (A) or infected with lentivirus encoding scrambled siRNA (siNC) or TRAF3 siRNA (siTRAF3; B) and then left 
untreated (mock) or stimulated with IL-17 for 1 or 3 h. The induction of KC, IL-6, Cxcl2, and Ccl20 mRNA was analyzed by real-time PCR. (C) Traf3/ 
MEFs transduced with control retrovirus or retrovirus encoding mouse TRAF3 were left untreated (mock) or stimulated with IL-17 for 1 and 3 h. The 
induction of KC and IL-6 mRNA was measured by real-time PCR. (D and E) Mouse primary astrocytes (D) or human astrocyte cell line U87-MG (E) was 
infected with lentivirus encoding scrambled siRNA, TRAF3 siRNA, or Act1 siRNA (siAct1) and were left untreated (mock) or treated with IL-17 alone or 
IL-17 plus 10 ng/ml TNF. The expression of KC, IL-6, and Ccl20 mRNA was analyzed by real-time PCR. All gene expression above was shown as fold of 
induction relative to that of the untreated cells. *, P < 0.05; and **, P < 0.01 (Student’s t test). Data are representative of three (A–E) independent ex-
periments (mean and SEM).JEM VOL. 207, November 22, 2010 
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TRAF3 expression. GFP-positive cells were then sorted out 
by flow cytometry and transfected with NF-B luciferase 
construct. After transduction, the cells were stimulated with 
or without IL-17. Knockdown of TRAF3 significantly in-
creased IL-17–mediated NF-B luciferase activity (Fig. S1 A). 
Similarly,  TRAF3-deficient  MEFs  showed  much  higher   
NF-B luciferase activity than WT MEFs, whereas TRAF3 
restoration  into  TRAF3-deficient  MEFs  significantly  sup-
pressed IL-17–induced NF-B luciferase activity (Fig. S1 B). 
Together, these results indicate that TRAF3 plays an impor-
tant inhibitory role in IL-17–mediated NF-B activation   
and transcription.
To  further  confirm  the  negative  role  of  TRAF3  in   
IL-17–mediated pathways, we checked the expression of   
IL-17–induced genes. Although IL-17 strongly induced the 
expression of inflammatory cytokines or chemokines, includ-
ing KC, IL-6, Cxcl2, and Ccl20 in HeLa cells, TRAF3 over-
expression dramatically suppressed IL-17–induced expression 
of these genes (Fig. 2 A). On the contrary, knockdown of 
TRAF3 in HeLa cells significantly increased IL-17–mediated 
gene expression (Fig. 2 B and Fig. S1 C). The inhibitory 
phenomenon of TRAF3 was also found in the mouse cell 
system.  TRAF3  restoration  into  TRAF3-deficient  MEFs 
greatly reduced the IL-17–induced gene expression (Fig. 2 C). 
We also investigated the function of endogenous TRAF3 in 
regulating  IL-17–induced  production  of  proinflammatory 
genes in the physiological relevant cell types like astrocytes 
and synoviocytes. We observed that knockdown of TRAF3 
in  mouse  primary  astrocytes  increased  the  IL-17–induced 
production of inflammatory genes, including KC, IL-6, and 
Ccl20, whereas knockdown of Act1 decreased the induction 
of those genes (Fig. 2 D). IL-17 has been known to synergize 
with TNF in the induction of the proinflammatory genes. 
Similarly, knockdown of TRAF3 increased, whereas knock-
down of Act1 decreased the synergy of IL-17 and TNF in 
induction of the proinflammatory genes in the primary mouse 
astrocytes (Fig. 2 D). Similar observations were also found in 
human astrocytes (Fig. 2 E) and human primary synoviocytes 
(Fig.  S1  D),  in  which  knockdown  of  TRAF3  increased, 
whereas knockdown of Act1 decreased IL-17–mediated or 
the combination of IL-17– and TNF-mediated induction of 
the proinflammatory genes. TRAF3 also dramatically sup-
pressed the synergy when low dose of TNF was used (Fig. S1, 
E and F). These data clearly show that endogenous TRAF3 
negatively regulates IL-17–mediated downstream gene in-
duction in different cell types.
IL-17 stimulation induces the recruitment of TRAF3  
to IL-17R
Because  our  aforementioned  results  showed  that  TRAF3 
plays a general inhibitory role in IL-17–mediated pathways, 
including NF-B and MAPKs, we next checked whether 
TRAF3 functions at the receptor level through its recruit-
ment to IL-17R upon IL-17 stimulation. To test the hypoth-
esis, we generated HeLa cell lines stably expressing Flag-tagged 
IL-17R and performed coimmunoprecipitation assay in a 
signal-dependant way. IL-17 stimulation led to transient inter-
action of IL-17R with TRAF3. But the recruitment of  TRAF3 
to IL-17R is slower compared with that of Act1 to IL-17R, 
implying that IL-17R may first recruit Act1 for activation 
signaling and then recruit TRAF3 for timely turning off the 
activation signaling (Fig. 3 A).
There are five receptors, IL-17RA to IL-17RE, in the 
IL-17R superfamily. Because both IL-17RA and IL-17RC 
are  required  for  IL-17  signaling,  we  wondered  whether 
TRAF3 also binds to IL-17RC. We checked the interaction 
of TRAF3 with all the five receptors in 293 cells by over-
expression. We found that TRAF3 indeed bound to IL-17RC, 
in addition to IL-17RA (Fig. S2 A). TRAF3 only weakly   
interacted with IL-17RE but did not associate with IL-17RB or 
IL-17RD. We further confirmed the interaction of TRAF3 
with  IL-17RC  in  IL-17  signaling. We  generated  HeLa   
cells stably expressing Flag-tagged IL-17RA and HA-tagged   
IL-17RC and performed immunoprecipitation. We found 
Figure 3.  TRAF3 is recruited to IL-17R upon IL-17 stimulation.  
(A) HeLa cells stably expressing M2 (Flag)–IL-17RA were either left un-
treated or treated with IL-17 for 1, 3, 6, or 9 min. Whole cell lysates were 
immunoprecipitated (IP) with anti-M2 or control IgG and followed by 
immunoblotting with anti-TRAF3, anti-Act1, and anti-M2. Whole cell 
lysates were also immunoblotted with anti-Act1, anti-TRAF3, or anti-M2 
to check the expression level of individual proteins or with anti–p-IB to 
check IL-17 responsiveness. (B) HeLa cells stably expressing M2–IL-17RA 
and HA–IL-17RC were either left untreated or treated with IL-17 for 1, 3, 
6, 9, or 12 min. Whole cell lysates were immunoprecipitated with anti-
TRAF3 and followed by immunoblotting with anti-M2, anti-HA, and anti-
TRAF3. (C and D) HeLa cells were left untreated or treated with IL-17 for 
5, 10, or 20 min. Whole cell lysates were immunoprecipitated with IgG or 
anti–IL-17R (C) or IgG or anti-TRAF3 (D) and followed by immunoblotting 
with anti-TRAF3 or anti–IL-17R. Data are representative of three (A, C, 
and D) or two (B) independent experiments.2652 TRAF3 suppresses IL-17R signaling | Zhu et al.
with  IL-17R  antibody.  Similar  results  were  found  that 
TRAF3 interacted with IL-17R in an IL-17 signal–dependant 
way (Fig. 3 D). Because IL-17 induced the recruitment of 
TRAF3 to IL-17R, we looked for the potential TRAF3-
binding domains or sites in the IL-17R. The cytoplasmic part 
of IL-17R has been reported to consist of SEFIR, TILL 
(TIR-like loop), and distal domains with different functions 
(Fig. S3 A; Maitra et al., 2007). Through coimmunoprecipi-
tation in HEK293 cells, TRAF3 was shown to strongly inter-
act with IL-17R upon overexpression, as we previously 
observed (Qian et al., 2007). However, deletion of the distal 
domain of IL-17R blocked the interaction of IL-17R and 
TRAF3, whereas deletion of SEFIR domain or TILL do-
main had no effect or partial effect, respectively, indicating 
that TRAF3 binds to the distal domain of IL-17R (Fig. S3 B). 
that IL-17 stimulation led to signal-dependent association of 
TRAF3 with IL-17RC, similar to the interaction of TRAF3 
with IL-17RA (Fig. 3 B). These data suggest that TRAF3 
binds  to  IL-17RA–IL-17RC  heterodimers  to  inhibit   
IL-17 signaling.
To avoid the overexpression system, we further tested the 
interaction of endogenous IL-17R and TRAF3 in HeLa cells 
in IL-17 signaling. Whole cell lysates were immunoprecipi-
tated with anti–IL-17R or control IgG and Western blotted 
with anti-TRAF3. Consistent with the results from the over-
expression system, IL-17 stimulation also led to transient as-
sociation of IL-17R with TRAF3 (Fig. 3 C). We confirmed 
that the IL-17R antibody did not cross react with IL-17RC 
(Fig. S2 B). We next immunoprecipitated TRAF3 with anti-
TRAF3 or control IgG and checked the binding protein 
Figure 4.  TRAF3 competes with Act1 to interact with IL-17R. (A) HEK293 cells were transfected with the combined plasmids as indicated. Whole 
cell lysates were immunoprecipitated (IP) with anti-M2, followed by immunoblotting (IB) with anti-M2, anti-Myc, or anti-HA. (B) TRAF3 deletion mutants 
are shown in the top panel. HEK293 cells were transfected with plasmids encoding HA-tagged IL-17R and empty vector (EV) or Flag (M2)-tagged TRAF3 
or its deletion mutants. Whole cell lysates were immunoprecipitated with anti-M2 and then immunoblotted with anti-HA or anti-M2. (C) HEK293 cells 
were transfected with the combined plasmids as indicated. Whole cell lysates were immunoprecipitated with anti-M2, followed by immunoblotting with 
anti-M2 or anti-Myc. Whole cell lysates were also immunoblotted with anti-M2, anti-Myc, or anti-HA. (D and E) HEK293 cells infected with lentiviruses 
encoding scrambled (siNC) or Act1 (siAct1) siRNA (D) or scrambled or TRAF3 (siTRAF3) siRNA (E) were then transfected with expression plasmids encoding 
M2–IL-17R and HA-TRAF3 (D) or M2–IL-17R and HA-Act1 (E). Whole cell lysates were immunoprecipitated with anti-M2, followed by immunoblotting 
with anti-HA or anti-M2. (F) TRAF3-deficient MEFs first transduced with retrovirus encoding empty vector (EV), mouse full-length TRAF3, or TRAF3 lacking 
TRAF domain (TRAF3 dTRAF) were then left untreated (mock) or stimulated with IL-17 for 1 or 3 h. Induction of KC and IL-6 mRNA was analyzed by real-
time PCR and shown as fold of induction relative to the individual untreated MEFs. **, P < 0.01; and ***, P < 0.001 (Student’s t test). Data are representa-
tive of three (A and C–F) or four (B) independent experiments (mean and SEM in F).JEM VOL. 207, November 22, 2010 
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and the distal deletion mutant but not the SEF deletion mu-
tant showed interaction with TRAF6 (Fig. S4 C), indicating 
that TRAF6 binds to the SEF domain of IL-17R. Because we 
previously found that Act1 also interacts with IL-17R through 
the SEF domain (Qian et al., 2007) and the SEF domain has 
no obvious TRAF-binding site, these results suggest that 
TRAF6 may associate with IL-17R through Act1.
To prove the physiological function of the competitive 
binding of TRAF3 to IL-17R, we made use of the TRAF 
domain deletion mutant of TRAF3 and performed a func-
tional restoration assay in TRAF3-deficient MEFs (Fig. 4 F). 
Restoration of WT TRAF3 resulted in strong inhibition of 
IL-17–induced IL-6 or KC production both at 1 and 3 h after 
stimulation. However, the deletion mutant of TRAF3, which 
cannot bind to IL-17R, no longer dramatically suppressed 
IL-17–induced gene expression of IL-6 and KC, indicating 
that TRAF3 exerts its negative role in IL-17 signaling through 
its competitive binding to IL-17R. All together, our results 
suggest that the binding of TRAF3 to IL-17R disrupts the 
formation of the IL-17R–Act1–TRAF6 activation complex, 
resulting in suppression of IL-17–mediated signaling and in-
duction of downstream genes.
TRAF3 represses IL-17–induced expression of inflammatory 
factors in vivo
To study the physiological role of TRAF3 in IL-17–mediated 
pathways, we generated TRAF3 transgenic mice. Five founders 
were obtained by genotyping through PCR (unpublished 
data), and two founders were characterized in more detail. 
The TRAF3 expression level was significantly higher in these 
two transgenic founders (TG1 and TG2) than that in WT 
controls (WT1 and WT2) in all of the tissues checked, in-
cluding brain, spleen, and liver (Fig. 5 A). These two found-
ers were therefore used for further investigations. We next 
generated adenovirus system for efficient delivery of virus 
and high expression of mouse IL-17 in mice. The IL-17 was 
efficiently expressed in different mouse tissues checked, in-
cluding brain and spinal cord. It is worth noting that the 
overexpression level of IL-17 in different tissues is quite simi-
lar between TRAF3 transgenic mice and WT controls. So 
we continued to use the adenovirus system to overexpress 
IL-17 in vivo and assess the effects of TRAF3 in IL-17–
mediated gene induction in vivo. IL-17 significantly induced 
the expression of inflammatory factors like KC, IL-6, and 
MMP3 in different tissues checked, including brain and spinal 
cord of WT mice by real-time PCR. However, the induc-
tion of those inflammatory factors by IL-17 was dramatically 
suppressed in TRAF3 transgenic mice (Fig. 5 B). We next 
measured the protein level of IL-17, IL-6, and KC in the   
serum of WT and transgenic mice by ELISA. Consistently, 
whereas the IL-17 protein level was slightly increased in the 
sera of TRAF3 transgenic mice, the protein levels of IL-6 
and KC were greatly reduced in the sera of TRAF3 trans-
genic mice compared with WT mice (Fig. 5 C). These results 
suggest that TRAF3 suppresses IL-17–induced expression of 
inflammatory factors in vivo.
We next looked into the primary structure of IL-17R and 
observed two potential TRAF3-binding sites, TB1 (AXEE) 
and TB2 (PXEE; Fig. S3 A). To examine whether these two 
sites are important for the association of IL-17R to TRAF3, 
we point-mutated the sites and performed immunoprecipita-
tion assay. Mutation of the TB2 site severely impaired the inter-
action of IL-17R and TRAF3, whereas mutation of the TB1 
site had no or mild effect, suggesting that TRAF3 binds to the 
TB2 site of IL-17R (Fig. S3 C). All together, our data suggest 
that TRAF3 functions at the receptor level in regulating   
IL-17–mediated signaling.
The binding of TRAF3 to IL-17R interferes with the 
formation of the IL-17R–Act1–TRAF6 activation complex
Given the fact that both TRAF3 and Act1 bind to IL-17R 
but function in the opposite way, we reasoned that TRAF3 
could compete with Act1 to interact with IL-17R and there-
fore inhibit the formation of the IL-17R–Act1 activation   
signaling complex. To test this hypothesis, we transfected 
HEK293 cells with different combinations of plasmids as in-
dicated in Fig. 4 A and performed coimmunoprecipitation. 
Indeed, the addition of TRAF3 severely suppressed the inter-
action of IL-17R with Act1, whereas the addition of Act1 
reduced the association of TRAF3 with IL-17R (Fig. 4 A). 
We then mapped the domains of TRAF3 to interact with 
IL-17R. TRAF3 contains Ring finger domain followed by 
zinc finger domain, coiled-coil domain, and TNF receptor–
associated factor (TRAF) domain (He et al., 2007). We made 
different deletion constructs as shown in Fig. 4 B and per-
formed coimmunoprecipitation to detect their interactions 
with IL-17R. We found that the constructs containing TRAF 
domain  associated  with  IL-17R,  whereas  those  constructs 
without TRAF domain did not, indicating that the TRAF 
domain  of  TRAF3  is  responsible  for  its  interaction  with   
IL-17R (Fig. 4 B). Consistently, the TRAF domain deletion 
mutant of TRAF3 did not inhibit the binding of IL-17R to 
Act1, proving that the TRAF domain of TRAF3 associates 
with IL-17R to interfere with the binding of Act1 to IL-17R 
(Fig. 4 C). To further confirm the competitive binding hy-
pothesis, we separately knocked down Act1 or TRAF3 and 
then checked protein interaction. We found that the association 
of TRAF3 with IL-17R was increased when Act1 expression 
was reduced (Fig. 4 D). Similarly, the binding of Act1 to IL-17R 
was enhanced when TRAF3 was knocked down (Fig. 4 E). 
These results strongly suggest that binding of TRAF3 to   
IL-17R dissociates the complex of Act1 and IL-17R.
Because TRAF6 has also been shown to be recruited to 
IL-17R (Schwandner et al., 2000; Qian et al., 2007), we 
checked  whether  TRAF3  also  competes  with  TRAF6  to 
bind to IL-17R. We transfected HEK293 cells with different 
combinations of plasmids as indicated in Fig. S4 and per-
formed  coimmunoprecipitation.  The  addition  of  TRAF3 
also severely suppressed the interaction of IL-17R and TRAF6 
(Fig. S4 A), whereas the TRAF3 mutant with TRAF domain 
deleted lost its suppressive effect (Fig. S4 B). We then mapped 
the domains of IL-17R to interact with TRAF6. Both WT 2654 TRAF3 suppresses IL-17R signaling | Zhu et al.
Figure 5.  TRAF3 represses IL-17–induced expression of inflammatory factors in vivo. (A) TRAF3 expression was checked by immuno-
blotting (IB) with anti-TRAF3 from lysates of brain, spleen, and liver from two WT control mice (WT1 and WT2) or two TRAF3 transgenic found-
ers (TG1 and TG2). (B and C) WT control or TRAF3 transgenic mice (T3TG; n = 4/group) were injected i.v. with adenovirus encoding empty vector 
(Ad-EV) or mIL-17 (Ad–IL-17) for 4 d. IL-17, KC, IL-6, and Mmp3 mRNA in the brain and spinal cord was measured by real-time PCR (B), and  
IL-17, IL-6, and KC protein in the serum was measured by ELISA (C). (D) TRAF3 expression was checked by immunoblotting with anti-TRAF3 from 
lysates of B16 cells and brain and spinal cord from four pairs of mice injected intracerebroventricularly with lentivirus encoding scrambled 
siRNA (siNC) or TRAF3 siRNA (siTRAF3). (E) C57BL/6 mice were injected intracerebroventricularly with lentivirus encoding scrambled siRNA or 
TRAF3 siRNA (n = 4/group) for 4 d and then were injected i.v. with adenovirus encoding empty vector or mIL-17 for 4 d. IL-17, KC, IL-6, and 
Mmp3 mRNA in the brain and spinal cord was measured by real-time PCR. mRNA expression is shown as fold of induction relative to that in 
the WT control mice. *, P < 0.05; and **, P < 0.01 (Student’s t test). Data are representative of three (A–C) or two (D and E) independent experi-
ments (mean and SEM in B, C, and E).JEM VOL. 207, November 22, 2010 
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compared with control mice (Fig. 6 D). The H&E staining 
also showed increased infiltration of inflammatory cells in the 
TRAF3 knockdown mice (Fig. 6 E). Similarly, real-time analy-
sis showed increased production of inflammatory genes dur-
ing EAE induction in the TRAF3 knockdown mice (Fig. 6 F). 
Our results from RNAi-mediated knockdown of TRAF3 in 
mice in vivo are consistent with the data obtained from the 
TRAF3 transgenic mice showing that TRAF3 dramatically 
suppressed EAE development.
TRAF3-mediated suppression of IL-17 signaling in the CNS 
is likely responsible for its control of EAE development
To fully prove that TRAF3 in the CNS plays a major role in 
controlling EAE development, bone marrow transfer experi-
ments were conducted. Both TRAF3 transgenic and WT 
control mice were irradiated to have their hematopoietic cells 
removed and then injected i.v. with WT bone marrow cells. 
After reconstitution, the mice were immunized with MOG 
(35–55) for EAE development. Similar to the results from 
TRAF3 transgenic mice (Fig. 6 A), the disease onset was de-
layed, and the severity and incidence of EAE induction was 
dramatically reduced in TRAF3 transgenic mice transplanted 
with WT bone marrow cells (Fig. 7 A), indicating that 
TRAF3 likely controls EAE development through its nega-
tive function in the CNS-resident cells.
Because we clearly showed that TRAF3 inhibited IL-17–
mediated signaling and downstream gene induction of in-
flammatory factors both in vitro and in vivo (Figs. 1, 2, and 5), 
we next checked whether TRAF3-mediated suppression of 
IL-17 signaling is really responsible for the observed inhibi-
tory effect on EAE in the TRAF3 transgenic mice. Th17 cell 
transfer can induce EAE, which is normally used for assessing 
the IL-17–mediated effect on EAE induction. We found 
that EAE induced by Th17 cell transfer was dramatically 
suppressed in the TRAF3 transgenic mice compared with 
control mice (Fig. 7 B), similar to MOG-induced EAE 
(Fig. 6 A), indicating that TRAF3-mediated suppression of 
IL-17 signaling is mainly responsible for its suppressive effect 
on EAE.
It is known that TRAF3 is essential for TLR-mediated 
production of IL-10 and type I IFN, which have been shown 
to play important inhibitory roles in EAE development   
(Cua et al., 2001; Fillatreau et al., 2002; Prinz et al., 2008).   
We next checked whether TRAF3-mediated production of 
IL-10 and type I IFN was involved in the observed suppres-
sive effect of TRAF3 on EAE induction. We first assessed the 
expression of IL-10 and type I IFN in the TRAF3 transgenic 
mice during EAE induction. Although undetectable in the 
sera by ELISA (not depicted), IL-10 was potently induced in 
the spinal cords of both TRAF3 transgenic mice and control 
mice (Fig. 7 C). But there was no significant difference in the 
induction level of IL-10 between the transgenic and control 
groups. Similarly undetectable in the sera (not depicted), 
both IFN4 and IFN were also induced in the CNS during 
EAE, but the induction levels were much lower compared 
with that of IL-10 (Fig. 7 C). The induction of IFN4 and 
To confirm the results from the TRAF3 transgenic mice, 
we set up an RNAi approach to knock down TRAF3 in 
mice in vivo through lentiviral system, which has been re-
ported to be efficient for gene knockdown in the CNS (Saijo 
et al., 2009; Regev et al., 2010). The lentivirus for silencing 
TRAF3 was concentrated and checked for knockdown effi-
ciency (>90%) in mouse B16 cells (Fig. 5 D) and then in-
jected intracerebroventricularly to knock down TRAF3 in 
the CNS in mice. We found that knockdown efficiency of 
TRAF3 was >50% in both brain and spinal cord (Fig. 5 D). 
Thus, we used this in vivo knockdown approach to study the 
function of TRAF3 and found that knockdown of TRAF3 
in mice significantly increased IL-17–induced production of 
the inflammatory genes in both brain and spinal cord (Fig. 5 E), 
which is consistent with the results from the TRAF3 trans-
genic mice (Fig. 5 B).
TRAF3 critically controls EAE development
IL-17 has been shown to play critical roles in the development 
of autoimmune diseases like EAE. In this study, we have dem-
onstrated  that  TRAF3  plays  important  negative  roles  in   
IL-17–mediated signaling pathways and downstream gene in-
duction of inflammatory factors both in vitro and in vivo. We 
next explored whether TRAF3 modulates the development of 
the IL-17–mediated autoimmune disease EAE. Whereas EAE 
was strongly induced after MOG immunization in the WT 
control mice with a peak clinical score of 3.2, the disease sever-
ity was dramatically reduced in TRAF3 transgenic mice with 
the peak clinical score of 1.5 (Fig. 6 A). The onset of EAE in-
duction was also significantly delayed in the TRAF3 transgenic 
mice, occurring at day 11 after MOG immunization, com-
pared with WT control mice with the onset at day 7. Similarly, 
the EAE disease incidence (57%) was greatly reduced in the 
TRAF3 transgenic mice, compared with the 100% incidence 
in WT control mice (Fig. 6 A).
Local  IL-17–mediated  signaling  is  considered  to  be   
important for inducing plenty of inflammatory factors to   
recruit numerous immune cells to CNS, resulting in inflam-
mation and tissue disruption. Consistent with the clinical 
scores, histological analyses by hematoxylin and eosin (H&E) 
and luxol fast blue staining showed that inflammatory infil-
tration and demyelination were much reduced in the spinal 
cords of TRAF3 transgenic mice after MOG immunization 
compared with WT mice (Fig. 6 B). Furthermore, real-time 
PCR analyses showed that although MOG immunization 
strongly induced the expression of inflammatory factors like 
KC, Cxcl2, IL-6, and Mmp3 in the spinal cords and brains of 
WT mice, the induction of these inflammatory genes was 
dramatically decreased in the spinal cords and brains of the 
TRAF3 transgenic mice. These results suggest that TRAF3 
controls EAE development likely through its inhibitory 
role in IL-17–mediated gene induction of inflammatory 
factors (Fig. 6 C).
We  also  performed  EAE  induction  after  TRAF3  was 
knocked down in the CNS. We observed significantly in-
creased EAE clinic scores in the TRAF3 knockdown mice 2656 TRAF3 suppresses IL-17R signaling | Zhu et al.
To  really  prove  that  the  observed  inhibitory  effect  of 
TRAF3 on EAE development is not mainly through IL-10 
and type I IFN, we used the blocking antibodies of IL-10 and 
IFNAR1 and then performed EAE induction. As expected, 
the antibody blockage of IL-10 and IFNAR1 increased the 
IFN was only slightly increased in the TRAF3 transgenic 
mice compared with control mice (Fig. 7 C). All together, 
we unexpectedly observed no big difference of IL-10 and 
type I IFN production between the transgenic and control 
mice during EAE induction.
Figure 6.  TRAF3 critically controls EAE development. (A–F) WT control mice or TRAF3 transgenic (T3TG) mice were immunized with MOG (35–55) to 
induce EAE (A–C), or WT mice were injected intracerebroventricularly with lentivirus encoding scrambled siRNA (siNC) or TRAF3 siRNA (siTRAF3; n = 5–6/
group) for 4 d and then were immunized with MOG (35–55) to induce EAE (D–F). (A and D) Mean clinical scores (±SEM) and disease incidence were  
calculated daily according to the standards described in Materials and methods. (B and E) The spinal cords were histologically analyzed by H&E (B and E)  
or luxol fast blue staining (B) 16 d after immunization. The right panels show the magnifications of the boxed areas in the left panels. Bars, 50 µm.  
(C and F) KC, IL-6, MMP3, and Ccl2 (C) or KC and IL-6 mRNA (F) in the spinal cords or brains 0, 14, or 28 d after immunization was measured by real-time  
PCR. Expression of mRNA is shown as fold of induction relative to the untreated WT control mice. *, P < 0.05; and **, P < 0.01 (Student’s t test). Data are 
representative of four (A), three (B and C), or two (D–F) independent experiments (mean and SEM in A, C, D, and F).JEM VOL. 207, November 22, 2010 
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IL-17–mediated signal transduction, the negative regulation 
of IL-17 signaling still remains largely unknown (Shen et al., 
2009; for review see Qian et al., 2010). In this study, we 
identify the first receptor proximal negative regulator TRAF3 
in IL-17–mediated signaling associated with autoimmune 
diseases. TRAF3 was transiently recruited to IL-17R upon 
IL-17 stimulation. Binding of TRAF3 to IL-17R interfered 
with the formation of the activation complex IL-17R–Act1–
TRAF6,  resulting  in  suppressed  IL-17–mediated  signaling 
and suppressed induction of inflammatory genes. Moreover, 
TRAF3 also inhibited IL-17–induced expression of inflam-
matory  cytokines  and  chemokines  in  vivo.  Consistently, 
TRAF3 suppressed the development of both MOG-induced 
EAE and Th17 transfer–induced EAE. Collectively, our re-
sults suggest that TRAF3 functions as an IL-17R proximal 
regulator in critical control of IL-17–mediated inflammatory 
responses and autoimmune diseases like EAE.
EAE clinical scores in both TRAF3 transgenic mice and con-
trol mice (Fig. 7 D). However, under the same condition   
of the antibody blockage, the EAE clinical scores were dra-
matically reduced in the TRAF3 transgenic mice compared 
with control mice (Fig. 7 D), indicating that the production 
of IL-10 and type I IFN is not important for the suppressive 
effect on EAE in the TRAF3 transgenic mice. Collectively, 
our results suggest that TRAF3-mediated suppression of   
IL-17 signaling is responsible for its inhibitory regulation of 
EAE development.
DISCUSSION
Investigations from mouse models have shown that IL-17 
plays critical roles in the pathogenesis of many inflammatory 
diseases, although the evidence for effective anti–IL-17 ther-
apy in human autoimmune diseases is still lacking (Jäger et al., 
2009). Although some recent studies have begun to uncover 
Figure 7.  TRAF3 controls EAE development likely through its suppression of IL-17 signaling. (A) WT control or TRAF3 transgenic (T3TG) mice 
were first lethally irradiated and then reconstituted with WT bone marrow cells by i.v. injection. 8 wk after reconstitution, the mice were immunized with 
MOG (35–55) to induce EAE. (B) Lymphocytes from LNs of mice 10 d after MOG immunization were cultured with MOG and IL-23 for 4 d. These TH17 cells 
were then injected i.v. into sublethally irradiated WT or TRAF3 transgenic mice. Mean clinical scores (±SEM) and disease incidence were calculated daily. 
(C) IL-10, IFN4, IFN, and IL-17 mRNA was measured by real-time PCR in the spinal cords (SC) from TRAF3 transgenic or WT mice 14 or 28 d after MOG 
immunization (n = 6/group). Expression of mRNA is shown as fold of induction relative to naive, unmanipulated WT mice. (D) TRAF3 transgenic or WT 
mice (n = 5/group) were injected i.v. with IL-10 and IFNAR1 blocking antibodies or appropriate isotype controls, respectively at 0, 4, 8, 12, 16, or 20 d after 
MOG immunization. Mean clinical scores (±SEM) and disease incidence were calculated daily. *, P < 0.05 (Student’s t test). Data are representative of three 
(A) or two (B–D) independent experiments.2658 TRAF3 suppresses IL-17R signaling | Zhu et al.
recruited to IL-17R upon IL-17 stimulation, suggesting that 
TRAF3 really works at the receptor level. We recently char-
acterized Act1 as an essential adaptor in IL-17–mediated sig-
naling and inflammatory pathogenesis of autoimmune diseases 
(Qian et al., 2007). Because both TRAF3 and Act1 associate 
with IL-17R but function in the opposite way, we propose 
that TRAF3 may interfere with the binding of Act1 to IL-17R. 
Indeed, overexpression and knockdown experiments con-
firmed that TRAF3 competes with Act1 to interact with   
IL-17R. Moreover, TRAF3 also competes with TRAF6 to 
associate with IL-17R. Importantly, TRAF3 almost lost its 
inhibitory function when its binding domain to IL-17R was 
deleted, which is consistent with the competition mechanism 
for TRAF3 to function. Besides, when mapping the domains 
of IL-17R to interact with TRAF6, we unexpectedly found 
that TRAF6 interacts with the SEF domain instead of the 
TRAF-binding site in the distal domain used by TRAF3.   
As Act1 has been proved to interact with the SEF domain of 
IL-17R, these findings suggest that TRAF6 likely binds to 
IL-17R through Act1, which has TRAF6-binding sites (Qian 
et al., 2007). Our data that TRAF3 and Act1 bind to differ-
ent domains of IL-17R and compete with each other to as-
sociate with the receptor suggest that binding of TRAF3 to 
IL-17R may lead to the conformational change of IL-17R 
and thus interfere with its association with Act1, resulting in 
the subsequent suppression of downstream signaling and in-
duction of inflammatory genes.
TRAF3 has been found to be a critical regulator in both 
innate and adaptive immunity. It is an essential signaling adap-
tor in type I IFN producing signaling pathways for antiviral 
immunity, while it also controls noncanonical NF-B activa-
tion through degrading NIK in CD40 and BAFF-mediated 
signaling in regulation of B cell functions. In contrast to its 
negative role in CD40 signaling, TRAF3 plays a positive role 
in LMP1-mediated signaling and functions, suggesting that 
TRAF3 may use different mechanisms to function in differ-
ent signaling pathways. In this study, we found TRAF3 func-
tions in a new signaling pathway with a different signaling 
mechanism. Although CD40 and BAFF lead to TRAF3 deg-
radation through the cIAP1/2 signaling complex to turn on 
signaling, TRAF3 is not degraded upon IL-17 stimulation 
(Fig. S7). In addition, we demonstrate that TRAF3 competes 
with Act1 or TRAF6 to bind to IL-17R to turn off signaling 
for the prevention of continuous activation of inflammatory   
responses. Further dissection of mechanisms for TRAF3- 
mediated signaling would help us understand how TRAF3 ex-
erts diverse roles in physiological and pathological conditions.
IL-17 has been shown to be critical for pathogenesis of 
many autoimmune diseases in mouse models. EAE is the 
well-recognized mouse model with symptoms and pathology 
resembling MS. Because TRAF3 plays a critical role in the regu-
lation of IL-17–mediated inflammatory responses, we wondered 
whether TRAF3 is important in regulating IL-17–mediated 
pathology of EAE. For that purpose, we generated TRAF3 
transgenic mice. Consistent with the negative role of TRAF3 
in IL-17 signaling in cell culture system, TRAF3 inhibited 
IL-17 has been found to activate many signaling pathways 
for robust induction of proinflammatory cytokines and che-
mokines. Thus, negative regulation of IL-17 signaling is criti-
cal to shut off persistent inflammatory responses for the 
prevention of inflammation-mediated pathogenesis. So far, 
not much is known about how IL-17 signaling is negatively 
modulated (Shen et al., 2009). In this study, we found that 
IL-17 stimulation results in quick and transient recruitment 
of TRAF3 to IL-17R to timely turn off IL-17–mediated im-
mediate signaling, including NF-B and MAPKs. Consis-
tently,  we  observed  that  TRAF3  dramatically  suppressed 
IL-17–mediated induction of proinflammatory factors. It is 
noteworthy that IL-17 has been shown to synergize with 
TNF for amplification of inflammatory responses. Consistent 
with the repressive role of TRAF3 in IL-17 signaling, we 
found that TRAF3 also inhibited the synergistic induction of 
inflammatory genes by IL-17 and TNF. It has been reported 
that C/EBP- is responsible for the synergistic induction of 
IL-6 (Ruddy et al., 2004). Therefore, we checked whether 
TRAF3 affects the pathway of C/EBP in IL-17 signaling. 
We found that the induction of C/EBP- by IL-17 alone or 
by the combination of IL-17 and TNF was dramatically en-
hanced in TRAF3-deficient MEFs, whereas the induction 
was blocked in Act1-deficient MEFs (Fig. S5 A), which is 
consistent  with  the  general  inhibitory  role  of  TRAF3  in   
IL-17 signaling. In addition to its role in the transcriptional 
induction of inflammatory genes, IL-17 can also stabilize 
messenger RNAs (mRNAs) of chemokines induced by TNF 
for persistent inflammatory responses. We found that knock-
down of TRAF3 dramatically extended the half-life of the 
KC chemokine induced by TNF, whereas knockdown of   
Act1 greatly shortened the half-life of KC (Fig. S5, B–D),   
indicating that TRAF3 also plays an important inhibitory 
role in IL-17–mediated mRNA stability. Because TRAF6 is 
required  for  IL-17–mediated  NF-B  and  JNK  activation 
(Schwandner et al., 2000) but not required for IL-17–mediated 
mRNA stability of KC (Hartupee et al., 2009), these results 
indicate  that  TRAF3  functions  upstream  of  TRAF6  and 
likely at the IL-17R level for its general inhibitory effects in 
IL-17 signaling. Then we checked whether TNF affects the 
TRAF3–IL-17R interaction. We found that TNF did not 
affect the IL-17–induced interaction of TRAF3 with IL-17R 
(Fig. S5 E), suggesting that the synergy happens downstream 
of the IL-17R, likely through C/EBP or mRNA stability 
pathways. Because IL-17F also signals through IL-17RA and 
IL-17RC heterodimers like IL-17A, it is likely that TRAF3 
may also repress IL-17F signaling. Indeed, we found that 
overexpression  of  TRAF3  inhibited  whereas  knockdown   
of  TRAF3  enhanced  the  IL-17F–mediated  signaling   
(Fig. S6). Interestingly, IL-17RA is also required for IL-17E 
(IL-25)–mediated function. It remains to be determined 
whether TRAF3 also plays a similar inhibitory role in IL-25–
mediated signaling.
Deletion and point mutation analyses revealed that one 
TRAF3-binding site (PAEE) was responsible for IL-17R to 
associate with TRAF3. We further found that TRAF3 was JEM VOL. 207, November 22, 2010 
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MATERIALS AND METHODS
Mice.  To  generate  TRAF3  transgenic  mice,  cDNA  encoding  mouse 
TRAF3 was cloned into the plasmid pCAGGS (provided by J. Miyazaki, 
Osaka University, Suita, Osaka, Japan). Transgene-positive mice were iden-
tified  by  PCR  using  primers  derived  from  the  transgene  construct  and 
TRAF3 cDNA. The primer sequences used are as follows: sense primer   
5-GAAGGAAATGGGCGGGGAG-3 on the pCAGGS promoter and 
antisense  primer  5-CGGCACTTCTCGCACTTGTA-3  on  the  mouse 
TRAF3 cDNA. The mice were initially created on the CBA × C57BL/6 
background by Shanghai Biomodel Organism Science & Technology   
Development Co., Ltd. and then backcrossed to C57BL/6 for six generations. 
The TRAF3 transgenic mice and littermate controls at 6–12 wk of age were 
used for experiments. C57BL/6 mice were purchased from Shanghai Labo-
ratory Animal Center, Chinese Academy of Sciences. All mice were main-
tained in pathogen-free conditions. All animal experiments were performed 
in compliance with the guide for the care and use of laboratory animals and 
were approved by the institutional biomedical research ethics committee   
of  the  Shanghai  Institutes  for  Biological  Sciences  (Chinese  Academy   
of Sciences).
Reagents, cell lines, and constructs. Recombinant IL-17A, IL-17F, and 
TNF were purchased from R&D Systems. Anti-Flag (M2) antibody was 
purchased from Sigma-Aldrich. Anti-HA antibody was purchased from   
Covance. Antibodies to p-IB, p-p65, p-p38, p-JNK, ERK1/2, and   
C/EBP- were purchased from Cell Signaling Technology. Antibodies to 
p-ERK, IB, TRAF3, Act1, actin, IL-17RA, and Myc were purchased 
from Santa Cruz Biotechnology, Inc. Actinomycin D was purchased from 
Sigma-Aldrich. IFNAR1 and IL-10 neutralization antibody and relative iso-
type IgG were purchased from eBioscience.
HEK293  cells,  HeLa  cells,  human  astrocytes  U87-MG,  WT  and 
TRAF3-deficient MEFs (provided by G. Cheng, University of California, 
Los Angeles, Los Angeles, CA; He et al., 2006), human primary FLSs (pro-
vided by N. Li, Shanghai Jiao Tong University School of Medicine, Shang-
hai, China; Zhang et al., 2009), and mouse primary astrocytes, purified as 
described previously (Qian et al., 2007), were maintained in DME supple-
mented with 10% (vol/vol) FBS (Hyclone), 100 µg/ml penicillin G, and   
100 µg/ml streptomycin. HA- or M2 (Flag)-tagged TRAF3 or M2 (Flag)-
tagged IL-17R and their deletion mutants were generated by PCR and then 
cloned into pcDNA3.1.
Lentivirus-delivered siRNA gene knockdown. The two siRNA sequences 
for human TRAF3 gene knockdown are 5-GAAGGTTTCCTTGTTG-
CAGAATGAA-3 and 5-AGAGTCAGGTTCCGATGAT-3. The two 
siRNA sequences for human Act1 gene knockdown are 5-GCTTCAGAA-
CACTCATGTCTA-3 and 5-GCTGAAACCAATCCCAGAATA-3. 
The siRNA sequence for mouse TRAF3 gene is as described previously 
(Matsuzawa et al., 2008) and for mouse Act1 is 5-GTCAATTGCT-
GAAACCGAT-3. The scrambled control siRNA sequence is 5-GGAT-
CCTTGACAATACCAA-3.  The  siRNA  sequences  were  cloned  into 
pLSLG lentiviral vector. The respective lentiviral vectors and help vectors 
were transfected to 293FT cells for viral packaging. 60 h after transfection, 
virus was collected to infect target cells in the presence of 10 mg/ml poly-
brene (Sigma-Aldrich). After 4 d, the cells were used in the experiments as 
described in Figs. 1 (B and D–F), 2 (B, D, and E), and 4 (D and E) and Figs. S1 
(C–F), S5 (B–D), and S6.
Retrovirus-mediated gene expression. Flag-tagged TRAF3 was cloned 
into  pMSCV-IRES-GFP  vector.  For  restoration  of  gene  expression, 
TRAF3-deficient  MEFs  were  infected  by  viral  supernatant  suspensions   
obtained from 293FT cells transfected with Flag-tagged TRAF3 plasmid   
together with help vectors.
Coimmunoprecipitation. HEK293 cells were transfected with plasmids 
using the calcium phosphate transfection method, whereas HeLa cells were 
transfected with plasmids using Lipofectamine 2000 (Invitrogen) according 
IL-17–mediated induction of inflammatory mediators in vivo 
in TRAF3 transgenic mice. Consistently, TRAF3 delayed 
the onset of MOG-induced EAE and also dramatically sup-
pressed  the  disease  incidence  and  severity  of  EAE,  likely 
caused by inhibition of the production of inflammatory fac-
tors like cytokines, chemokines, and MMPs in CNS tissues. 
We also used a lentiviral system to knock down TRAF3 in 
mice and found that silencing of TRAF3 significantly in-
creased IL-17–mediated induction of proinflammatory genes, 
including cytokines, chemokines, and MMPs in CNS tissues, 
and EAE clinical pathology, which is consistent with the data 
from  the  TRAF3  transgenic  mice.  Thus,  our  experiments 
from both transgenic and knockdown mice have demonstrated 
the critical control role of TRAF3 in EAE development. Fur-
ther research is still necessary to uncover the importance of 
TRAF3 in the control of other autoimmune diseases such as 
CIA and inflammatory bowel disease. It also remains to be de-
termined whether there are polymorphisms in TRAF3 that 
may account for some cases of autoimmunity.
It has been shown that TRAF3 is essential for TLR- 
mediated production of IL-10 and type I IFN, which are im-
portant suppressors of EAE development. TRAF3 is supposed 
to mediate the production of IL-10 and type I IFN because 
of the adjuvant effect to activate TLR signaling during EAE 
induction. Interestingly, we unexpectedly observed no sig-
nificant change of IL-10 and only slight increase of type   
I IFN in the CNS of TRAF3 transgenic mice during EAE 
induction. One explanation could be that the endogenous 
TRAF3 expression level in the CNS may be high enough to 
mediate TLR signaling so that the increased TRAF3 expres-
sion in the transgenic mice only had a mild effect in the   
promotion of type I IFN and IL-10 production. Another   
possibility of no difference of IL-10 production could be that 
TRAF3 is essential for TLR-mediated IL-10 induction path-
way while it inhibits BAFF-mediated IL-10 production in   
B cells, both of which may be involved during EAE induc-
tion. These results suggest that IL-10 and type I IFN may not 
be responsible for the suppressed EAE in the transgenic mice. 
Indeed, our results from antibody blockage support the con-
clusion  that  IL-10  and  type  I  IFN  are  not  important  for 
TRAF3-mediated suppression of EAE development. We then 
performed Th17 cell transfer to assess the inhibitory effect of 
TRAF3 on EAE and indeed found that TRAF3 dramatically 
suppressed EAE induced by Th17 cell transfer, suggesting 
that TRAF3-mediated suppression of IL-17 signaling is re-
sponsible for its inhibitory regulation of EAE development.
In summary, we provide evidence for a previously un-
known key regulatory mechanism by discovering that TRAF3 
is critical in negative regulation of IL-17–mediated inflamma-
tory responses and pathogenesis of EAE. TRAF3 functions 
through its binding to IL-17R to interfere with the formation 
of the activation signaling complex IL-17R–Act1–TRAF6. 
To our knowledge, TRAF3 represents the first receptor proxi-
mal negative regulator in IL-17 signaling. TRAF3 may serve 
as a potential new target for intervention of inflammatory   
autoimmune diseases like MS.2660 TRAF3 suppresses IL-17R signaling | Zhu et al.
scored for disease severity using the EAE scoring scale: 0, no clinical signs;   
1, limp tail; 2, paraparesis (weakness, incomplete paralysis of one or two hind 
limbs); 3, paraplegia (complete paralysis of two hind limbs); 4, paraplegia 
with fore limb weakness or paralysis; and 5, moribund state or death.
Histology. Tissues for histological analysis were removed from mice 16 d 
after immunization and immediately fixed in 4% paraformaldehyde. Paraffin-
embedded 5–10-µm sections of spinal cord were stained with H&E or luxol 
fast blue and then examined by light microscopy.
Bone marrow chimeras. Recipient WT control mice or TRAF3 trans-
genic mice were lethally irradiated by 800 cGy before injection in the tail 
vein of 5 × 106 mixed bone marrow cells from donor WT mice. Irradiated, 
transplanted mice were fed with drinking water containing 2 mg/ml neomy-
cin sulfate (BioShop Canada Inc.) for 2 wk. After 8 wk of bone marrow   
reconstitution, EAE was induced as described in Induction and evaluation   
of EAE.
Adoptive transfer. Mice were immunized with MOG (35–55) plus com-
plete Freund’s adjuvant in conditions that induce active EAE. LNs were col-
lected 10 d later, and single-cell suspensions were prepared. Cells (6 × 106 
cells/ml) were cultured in RPMI 1640 medium (supplemented with 10% 
[vol/vol] FBS, 2 mM l-Gln, 1 mM sodium pyruvate, 100 IU/ml penicillin-
streptomycin, and 20 mM 2-mercaptoethanol) with 20 mg/ml MOG (35–55) 
and 20 ng/ml IL-23 for 4 d for Th17 cell differentiation. The Th17 cells 
were then injected i.v. into recipient mice (2 × 107 cells per mouse) that had 
been sublethally irradiated (500 rads) at 4 h before injection as described pre-
viously (Kang et al., 2010).
Intracerebroventricular  injection  of  lentiviruses.  Preparation  of   
lentivirus was described in Lentivirus-delivered siRNA gene knockdown. 
Viral supernatant was filtered through a 0.45-µm filter and concentrated by 
ultracentrifugation at 130,000 g for 2 h at 4°C and stored at 80°C. Before 
stereotaxic injection, the animals were anesthetized by intraperitoneal in-
jection of 4% chloral hydrate and placed in a stereotaxic frame. Injection 
coordinates relative to bregma were as follows: AP, 0.22 mm; ML, 1.15 
mm; and DV, 2.06 mm. A stainless steel cannula (5-µl Hamilton syringe) 
was inserted, and one deposit of 2 µl of lentivirus was slowly injected over 
a 2-min period. 5 min passed before the needle was removed to minimize 
retrograde flow along the needle track. After 4 d of intracerebroventricular 
injection,  EAE  was  induced  as  described  in  Induction  and  evaluation   
of EAE.
Statistics. Differences in the expression of genes between the groups were 
analyzed by the Mann-Whitney U test. Two-tailed Student’s t test was used 
to analyze the differences between the groups. One-way analysis of variance 
was initially performed to determine whether an overall statistically signifi-
cant change existed before using the two-tailed paired or unpaired Student’s 
t test. A p-value of <0.05 was considered statistically significant.
Online  supplemental  material. Fig. S1 shows that TRAF3 represses 
IL-17–induced NF-B activation and downstream gene induction. Fig. S2 
shows that TRAF3 interacts with IL-17RA and IL-17RC. Fig. S3 shows 
that TRAF3 binds to a TRAF-binding site in IL-17R. Fig. S4 shows that 
TRAF6 binds to the SEFIR domain of IL-17R and competes with TRAF3 to   
associate with IL-17R. Fig. S5 shows that TRAF3 suppresses IL-17–mediated   
induction of C/EBP- expression and stabilization of KC mRNA. Fig. S6   
shows that TRAF3 represses IL-17F–induced signaling. Fig. S7 shows 
that  IL-17  does  not  regulate  TRAF3  expression.  Online  supplemen-
tal  material  is  available  at  http://www.jem.org/cgi/content/full/jem 
.20100703/DC1.
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University School of Medicine, Shanghai, China) for support in the delivery of 
lentivirus into the CNS of mice.
to the manufacturer’s instructions. Cells were treated with or without IL-17 
at different time points. Cell extracts were incubated with 0.5 µg individual 
antibody and 20 µl protein A beads (GE Healthcare). After overnight incu-
bation, beads were washed four times with lysis buffer, separated by SDS-
PAGE, and analyzed by immunoblotting.
Immunoblot analysis. Cells or mouse tissues were directly lysed in Triton 
buffer (20 mM Hepes and 0.5% Triton X-100, pH 7.6) and separated by 
10% SDS-PAGE. Immunoblot analysis was performed by initial transfer of 
proteins onto polyvinylidene fluoride filters using Mini Trans-Blot (Bio-Rad 
Laboratories) and followed by a blocking step using Tris-buffered saline with 
0.1% Tween 20 plus 5% nonfat dried milk for 1 h at room temperature. The 
filters were then incubated with primary antibody overnight and subse-
quently washed. The blots were then incubated with a secondary antibody 
conjugated with HRP for 1 h at room temperature. After extensive washing 
of the blots, signals were visualized with chemiluminescent HRP substrate 
(Millipore). Sometimes, the same blot was stripped off and reprobed with 
other antibodies to check their proteins.
Real-time  RT-PCR. Total RNA was extracted from cells and mouse   
tissues with TRIZOL reagent (Invitrogen) according to the manufacturer’s 
instructions. The cDNA was synthesized with PrimeScript RT reagent kit 
(Takara Bio Inc.). The expression of the genes encoding KC, IL-6, CCL20, 
CXCL2, MMP3, IL-17, IL-10, IFN4, and IFN was quantified by real-
time PCR with SYBR Premix ExTaq kit (Takara Bio Inc.). All gene ex-
pression results were normalized to the expression of housekeeping gene 
Rpl13a. Amplification of cDNA was performed on an AbiPrism 7900 HT 
cycler (Applied Biosystems). To calculate mRNA t1/2, the mRNA level for 
the gene of interest was normalized to the Rpl13a mRNA level and plotted 
as log of the percentage of remaining mRNA versus time. The best fit to 
linear decay was determined, and the t1/2 was calculated from the intersec-
tion at the point corresponding to 50% residual RNA.
Luciferase reporter assay. HeLa cells or Traf3/ MEFs were cotrans-
fected with 250 ng of an NF-B–luciferase reporter and 25 ng of pRL-TK 
Renilla construct in each well of 12-well plates. After 24 h, cells were treated 
with 50 ng/ml IL-17 for 6 h before collection. Luciferase activity was mea-
sured with the Dual-Luciferase Reporter Assay system (Promega).
Adenoviral-mediated  cytokine  production  in  mice.  mIL-17  was 
cloned into pAdTrack-CMV and then recombined with pAdEasy-1. The 
recombinant plasmid Ad-mIL-17 or empty vector (Ad-EV) was transfected 
to 293A cells, and recombinant adenoviral plaques were isolated and further 
purified by two rounds of plaque assays as described previously (He et al., 
1998). After titration and dilution to a final concentration of 1010–1011 virus 
per ml PBS, the adenovirus containing empty vector or mIL-17 was injected 
i.v. into WT or TRAF3 transgenic mice. mIL-17 expression was evaluated 
4 d after injection.
ELISA. The cytokine and chemokine production from the sera of IL-17–
treated mice was assessed with IL-6, KC, and IL-17 ELISA kits (R&D Sys-
tems) according to the manufacturer’s instructions. A standard curve was 
generated  using  known  amounts  of  the  respective  purified  recombinant 
mouse cytokines or chemokines.
Induction  and  evaluation  of  EAE.  The  encephalitogenic  peptide   
of MOG used to induce EAE corresponded to residues (Met-Glu-Val-Gly-
Trp-Tyr-Arg-Ser-Pro-Phe-Ser-Arg-Val-Val-His-Leu-Tyr-Arg-Asn-Gly-Lys)   
35–55. The peptide was purchased from China Peptides Biotechnology. 
Acute EAE was induced by a subcutaneous immunization with 300 µg of the 
MOG (35–55) peptide in CFA containing 5 mg/ml heat-killed H37Ra 
strain of Mycobacterium tuberculosis (Difco) in the back region. Pertussis toxin 
(List Biological Laboratories, Inc.) at a dose of 200 µg/mouse in PBS was 
administered i.v. on the day of immunization and once more 48 h after. 
Mice were weighed and examined daily for disease symptoms. They were JEM VOL. 207, November 22, 2010 
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